Developing chemical reprogramming strategies of non-hepatocytes for liver regeneration
Ge D., Yang W., Ren H., Wang J.
Narrative Review, published in J Adv Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Adv Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40818621
- PMCID
- PMC13131455
- DOI
- 10.1016/j.jare.2025.08.018
- Citations
- 1
Abstract (original English)
Background Liver injury and the ensuing regenerative processes exert a profound impact on treatment outcomes. Conventional pharmacotherapy, nutritional adjuncts, and invasive interventions, despite their frequent utilization, often prove inefficacious. Chemical reprogramming, which employs small molecules to emulate extrinsic signaling cues, emerges as a promising therapeutic strategy for liver regeneration, analogous to the developmental processes governing cellular fate. However, its application in hepatic repair necessitates systematic integration. Aim of review This review synthesizes the role of chemical reprogramming in liver regeneration research. It first delineates the mechanisms underlying chemical reprogramming, emphasizing the pivotal role of small molecules in facilitating hepatic regeneration through the modulation of specific signaling pathways and epigenetic modifications. Additionally, it details the derivation of hepatocyte-like cells via chemical reprogramming within the realm of tissue engineering. The review further explores the role of chemical reprogramming in promoting in vivo liver repair and regeneration, particularly within the context of combinatorial therapeutic strategies. Key scientific concepts of review Chemical reprogramming induces the reprogramming of non-hepatic cells into hepatocyte-like cells through the precise regulation of cellular sign
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.